HHS mylan may have overcharged US epipen 127 billion

The sum is almost 3 times an suggested settlement the business announced in October. Grassley may be the chairman of the Senate Judiciary Committee, that started a probe of epi pen pricing this past year. Mylan failed to need a direct comment.

The Company, that was under passion to get exorbitant cost increases on those apparatus, said in October it decided to repay the U.S. government for $465 million later it had been accused of porting epi-pen together with all the Medicaid Drug Rebate Program being an generic therapy. Mylan, that didn’t acknowledge wrongdoing, has said it’s still attempting to finalize the compensation.


Our most popular topics on Managedcaremag.com